Skip to main content
. Author manuscript; available in PMC: 2017 Nov 28.
Published in final edited form as: Biochem J. 2014 Sep 1;462(2):315–327. doi: 10.1042/BJ20140174

Figure 4. HEXIM1 inhibits FOXA1 recruitment and H3K4me2 enrichment.

Figure 4

LNCaP cells stably transfected with control or HEXIM1miR were treated with vehicle, 10 nm R1881 or 10 μM bicalutamide for 90 min. Results show ChIP analyses of lysates immunoprecipitated with antibodies against AR (A), FOXA1 (B) or H3K4me2 (C) or control non-specific rabbit immunoglobin and PCR amplification of the enhancer regions of CDC20 (left-hand panels), CDK1 (middle panels) or PSA (right-hand panels). (D) C4-2 cells transfected with control vector or expression vector for FLAG-tagged HEXIM1 (fl-HEXIM1) were treated with vehicle, 10 nM R1881 or 10 μM bicalutamide for 90 min. Shown are ChIP analyses of lysates immunoprecipitated with antibodies against FOXA1 or control non-specific rabbit immunoglobin and PCR amplification of the enhancer region of CDK1. The results are means±S.E.M. of three independent experiments. aP <0.05 relative to R1881 alone, bP <0.05 relative to control transfected cells with the same treatment.